Author

JB Allred

Institution: Mayo Clinic

Observed institutions: National Institutes of Health, Albert Einstein College of Medicine, Carle Foundation Hospital, Mayo Clinic, Montefiore Medical Center, Johns Hopkins University, Missouri Valley Cancer Consortium, Mayo Clinic in Arizona, UPMC Hillman Cancer Center, National Cancer Institute, Mayo Clinic in Florida, Sidney Kimmel Comprehensive Cancer Center

OpenAlex ID: A5113551706

OT3-01-06: A Phase 2 Study Investigating the Safety, Efficacy and Surrogate Biomarkers of Response of 5-Azacitidine (5-AZA) and Entinostat (MS-275) in Patients with Advanced Breast Cancer.

2011 · RM Connolly, RC Jankowitz, et al. · Cancer Research · 8

Abstract P6-21-03: Phase I trial of intratumoral (IT) administration of a NIS-expressing derivative manufactured from a genetically engineered strain of measles virus (MV)

2019 · MC Liu, K-W Peng, et al. · Cancer Research · 6

Abstract P1-12-06: N0937 (Alliance): Preliminary results of a phase II clinical trial of cisplatin and the novel agent brostallicin in patients with metastatic triple negative breast cancer (mTNBC)

2012 · A Moreno-Aspitia, KM Rowland, et al. · Cancer Research

NCCTG N0338: effect of docetaxel and carboplatin on VEGF, PGE2, and immune cells in patients with stage II or III breast cancer.

2009 · BA Pockaj, P Mukherjee, et al. · Cancer Research

Works count: 4

Citation count: 14

H-index: 2

I10-index: